Lp(a) and risk of recurrent cardiac events in obese postinfarction patients

Obesity

Volumn 16, Issue 12, 2008, Pages 2717-2722

  Corsetti, James P ^a   Ryan, Dan ^a   Rainwater, David L ^b   Moss, Arthur J ^a   Zareba, Wojciech ^a   Block, Robert C ^a   Sparks, Charles E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HEPATIC LIPASE, HUMAN; INSULIN; LIPOPROTEIN A; TRIACYLGLYCEROL LIPASE;

ADULT; ANGINA PECTORIS; ARTICLE; BLOOD; FEMALE; GENETIC POLYMORPHISM; GENETICS; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MORTALITY; OBESITY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR;

ADULT; ANGINA PECTORIS; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; FEMALE; HUMANS; INSULIN; KAPLAN-MEIERS ESTIMATE; LIPASE; LIPOPROTEIN(A); MALE; MYOCARDIAL INFARCTION; OBESITY; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; YOUNG ADULT;

ANGINA;

EID: 58149299844     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.441     Document Type: Article

References (34)

1. Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation 2006;113:898-918.
2. Rea TD, Heckbert SR, Kaplan RC et al. Body mass index and the risk of recurrent coronary events following acute myocardial infarction. Am J Cardiol 2001;88:467-472.
3. Ness AR, Gunnell D, Hughes J et al. Height, body mass index, and survival in men with coronary disease: follow up of the diet and reinfarction trial (DART). J Epidemiol Community Health 2002;56:218-219.
4. Kaplan RC, Heckbert SR, Furberg CD, Psaty BM. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 2002;55:654-664.
5. Rana JS, Mukamal KJ, Morgan JP, Muller JE, Mittleman MA. Obesity and the risk of death after acute myocardial infarction. Am Heart J 2004;147:841-846.
6. Dagenais GR, Yi Q, Mann JF et al. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005;149:54-60.
7. Domanski MJ, Jablonski KA, Rice MM, Fowler SE, Braunwald E. Obesity and cardiovascular events in patients with established coronary disease. Eur Heart J 2006;27:1416-1422.
8. Widlansky ME, Sesso HD, Rexrode KM, Manson JE, Gaziano M. Body mass index and total and cardiovascular mortality in men with a history of cardiovascular disease. Arch Intern Med 2004;164:2326-2332.
9. Lopez-Jimenez F, Jacobsen SJ, Reeder GS et al. Prevalence and secular trends of excess body weight and impact on outcomes after myocardial infarction in the community. Chest 2004;125:1205-1212.
10. Kragelund C, Hassager C, Hildebrandt P, Torp-Pedersen C, Kober L. Impact of obesity on long-term prognosis following acute myocardial infarction. Int J Cardiol 2005;98:123-131.
11. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-880.
12. Moss AJ, Goldstein RE, Marder VJ et al. Thrombogenic factors and recurrent coronary events. Circulation 1999;99:2517-2522.
13. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-The evidence report, National Institutes of Health. Obes Res 1998;6(Suppl 2): 51S-209S..
14. Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High lipoproteinassociated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 2006;52:1331-1338.
15. Rainwater DL. Electrophoretic separation of LDL and HDL subclasses. Method Mol Bio 1998;110:137-151.
16. Moss AJ, Ryan D, Oakes D et al. Atherosclerotic risk genotypes and recurrent coronary events after myocardial infarction. Am J Cardiol 2005;96:177-182.
17. Berglund L, Ramakrishman R. Lipoprotein(a) an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004;24:2219-2226.
18. Enas EA, Chacko V, Senthilkumar A, Puthumana N, Mohan V. Elevated lipoprotein(a)-a genetic risk factor for premature vascular disease in people with and without standard risk factors: a review. Dis Mon 2006;52:5-50.
19. Anuurad E, Boffa MB, Koschinsky ML, Berglund L. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med 2006;26:751-772.
20. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease meta-analysis of prospective studies. Circulation 2000;102:1082-1085.
21. Shlipak MG, Simon JA, Vittinghoff E et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000;283:1845-1852.
22. Wattanakit K, Folsom AR, Chambless LE, Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2005;149:606-612.
23. Emanuele E, Peros E, Minoretti P et al. Relationship between apolipoprotein(a) size polymorphism and coronary heart disease in overweight subjects. BMC Cardiovasc Disord 2003;2:12.
24. Jia L, Bai H, Fu M. Relationship between plasma HDL subclasses distribution and apoA-I gene polymorphisms. Clin Chim Acta 2005;360:37-45.
25. Wang XL, Liu SX, McCreadie RM, Wilcken DE. Polymorphisms at the 5'-end of the apolipoprotein AI gene and severity of coronary artery disease. J Clin Invest 1996;98:372-377.
26. Zhang C, Lopez-Ridaura R, Rimm EB et al. Genetic variation in the hepatic lipase gene and the risk of coronary heart disease among US diabetic men: potential interaction with obesity. Diabetologia 2006;49:1552-1559.
27. Reguero JR, Cubero GI, Batalla A et al. Apolipoprotein A1 gene polymorphisms and risk of early coronary disease. Cardiology 1998;90:231-235.
28. Cohen JC, Vega GL, Grundy SM. Hepatic lipase: new insights from genetic and metabolic studies. Curr Opin Lipidol 1999;10:259-267.
29. Cobbaert C, Jukema JW, Zwinderman AH et al. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. J Am Coll Cardiol 1997;30:1491-1499.
30. Cantin B, Gagnon F, Moorjani S et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998;31:519-525.
31. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001;37:434-439.
32. Rainwater DL, Ludwig MJ, Haffner SM, VandeBerg JL. Lipid and lipoprotein factors associated with variation in Lp(a) density. Arterioscler Thromb Vasc Biol 1995;15:313-319.
33. Nakajima K, Hinman J, Pfaffinger D, Edelstein C, Scanu AM. Changes in plasma triglyceride levels shift lipoprotein(a) density in parallel with that of LDL independently of apolipoprotein(a) size. Arterioscler Thromb Vasc Biol 2001;21:1238-1243.
34. Tsimikas S, Bergmark C, Beyer RW et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003;41:360-370.